Centre Hospitalier Universitaire de la Réunion
chu-reunion.frLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
138
Active
35
Phase 3
5
Total enrollment
1,775,453
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| IXCHIQ | — | — | — | — | — | 1 | |
| plasma transfusion : PC-CHIK-V | — | — | — | — | — | 1 | |
| blood sample for BRCA2 mutation detection | — | — | — | — | — | 1 | |
| Biological samples | — | — | — | — | — | 1 |
Next readouts
- 2025-03-22
- 2026-04
- 2027-10-01
- 2037-05-05
Top conditions
- Diabetes5
- Lipodystrophy4
- Sport Injury3
- Obesity3
- Chikungunya Virus Infection3
- Leptospirosis3
- Cancer2
- Fetal Alcohol Spectrum Disorders2
Frequently asked questions about Centre Hospitalier Universitaire de la Réunion
- How many clinical trials does Centre Hospitalier Universitaire de la Réunion have on ClinicalTrials.gov?
- Centre Hospitalier Universitaire de la Réunion is listed as the lead sponsor on 138 clinical trials in ClinicalTrials.gov, 35 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Centre Hospitalier Universitaire de la Réunion's trials are in Phase 3?
- 5 of Centre Hospitalier Universitaire de la Réunion's trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does Centre Hospitalier Universitaire de la Réunion focus on?
- Centre Hospitalier Universitaire de la Réunion's most-studied conditions on ClinicalTrials.gov are Diabetes, Lipodystrophy, Sport Injury, Obesity, Chikungunya Virus Infection.
- When are Centre Hospitalier Universitaire de la Réunion's next clinical trial readouts?
- Centre Hospitalier Universitaire de la Réunion has 4 upcoming primary-completion readouts tracked here; the soonest is “Contribution of Oncogenetics in Breast Cancer in Reunion Epidemiology of Breast Cancer in Reunion: Study of the Reunion Mutation on BRCA2”, expected around 2025-03-22.